Clinical Trials
3 trialsNCT04337931 2024-02-13
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
Apexigen America, Inc.
Phase 2 Terminated
NCT03123783 2023-12-26
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab
Apexigen America, Inc.
Phase 1/2 Completed
NCT02482168 2023-12-20
Study of the CD40 Agonistic Monoclonal Antibody APX005M
Apexigen America, Inc.
Phase 1 Completed